Pipeline Alert: Gameto $44M Series C
Gameto raises $44M Series C. Target eClinical trial software & CDMO services. Email CEO Dina Radenkovic. 💰
Published on
Do not index
Do not index
🚀 Battle Card: Gameto
Quick trigger:
👤 Decision Maker in the News
- Dina Radenkovic, CEO 📧 dina@gametogen.com
💡 Why It Matters
- The $44M boost fuels acceleration of Phase 3 cell-engineered ovarian-aging therapies, highlighting investment in trial software and manufacturing capacity. This Gameto sales trigger signals priority spend on eClinical and CDMO partners. → Source
🎯 Core Pain Point
- Scaling GMP-compliant cell production for Phase 3 ovarian cell therapies
- Managing complex trial data capture and regulatory compliance
💰 What to Pitch
- Primary: eClinical Trial Management Software → streamline Phase 3 data capture & analysis
- Expansion: GMP Cell Therapy Manufacturing Service → scale granulosa & oocyte precursor production
🗺️ Quick Context
- HQ: New York, NY
- Employees: ≈ 75
- Rev: ≈ $0 (pre-revenue)
- Website: gametogen.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Gameto’s business.
- Medidata — eClinical Trial Software
- Unique edge: Industry-leading EDC & RTSM platform
- Evaluated by VP Clinical for data reliability
- Veeva Systems — eClinical Trial Software
- Unique edge: Unified CRM, regulatory & trial operations
- Evaluated by CMO for integrated compliance
- Oracle Health Sciences — eClinical Trial Software
- Unique edge: Scalable global trial infrastructure
- Evaluated by Head of R&D for analytics depth
- Lonza — CDMO / Cell Therapy Manufacturing
- Unique edge: Full-spectrum process development & scale-up
- Evaluated by VP Manufacturing for scale expertise
- Catalent — CDMO / Cell Therapy Manufacturing
- Unique edge: Flexible facility networks & fill-finish
- Evaluated by QA & VP Clinical for CMC support
- WuXi AppTec — CDMO / Cell Therapy Manufacturing
- Unique edge: End-to-end testing & production services
- Evaluated by QA for quality assurance
✅ Do-Now Checklist
Connect with Dina Radenkovic on LinkedIn / Email (dina@gametogen.com)
Reference the Gameto sales trigger in your first outreach
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get intel like this daily—no fluff, all pipeline. Don’t miss another Gameto sales trigger.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Streamlined Phase 3 eClinical trial data capture & analysis❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Dina
COMPANY = Gameto
DEPT = R&D
SIZE = 75
BOTTLENECK = scaling GMP-compliant cell production for Phase 3 ovarian cell therapies
EVENT = Closes $44M Series C Round
DETAIL = Closes $44M Series C Round
PAIN = managing complex trial data capture and regulatory compliance
SRC = https://vcnewsdaily.com/gameto/venture-capital-funding/ndxrvhgjbb
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = 150
EMP_EST = ≈ 75
REV_EST = ≈ $0M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 75-person R&D
Dina—noticed your R&D team is ≈ 75.
That’s when scaling GMP-compliant cell production for Phase 3 ovarian cell therapies slows growth.
We helped ≈ TBD fix this with Streamlined Phase 3 eClinical trial data capture & analysis.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ 150.
DM ≤45 words, TONE:
Saw your post about Closes $44M Series C Round — managing complex trial data capture and regulatory compliance.
Streamlined Phase 3 eClinical trial data capture & analysis. ≈ TBD.
Quick chat?